X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2019 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare ASTRAZENECA PHARMA with JUBILANT LIFE SCIENCES - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ASTRAZENECA PHARMA vs JUBILANT LIFE SCIENCES - Comparison Results

ASTRAZENECA PHARMA     Change

AstraZeneca Pharma India Limited (APIL) is a 90% subsidiary of the UK based AstraZeneca Pharmaceuticals, which is one of the world's leading pharma companies. APIL has interests in the six crucial areas of cardiovascular, respiratory, maternal health... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    ASTRAZENECA PHARMA JUBILANT LIFE SCIENCES ASTRAZENECA PHARMA/
JUBILANT LIFE SCIENCES
 
P/E (TTM) x 91.8 12.9 708.9% View Chart
P/BV x 20.2 1.8 1,106.9% View Chart
Dividend Yield % 0.0 0.6 -  

Financials

 ASTRAZENECA PHARMA   JUBILANT LIFE SCIENCES
EQUITY SHARE DATA
    ASTRAZENECA PHARMA
Mar-18
JUBILANT LIFE SCIENCES
Mar-18
ASTRAZENECA PHARMA/
JUBILANT LIFE SCIENCES
5-Yr Chart
Click to enlarge
High Rs1,2781,039 123.0%   
Low Rs883600 147.1%   
Sales per share (Unadj.) Rs228.4482.6 47.3%  
Earnings per share (Unadj.) Rs10.440.7 25.5%  
Cash flow per share (Unadj.) Rs16.367.4 24.1%  
Dividends per share (Unadj.) Rs03.00 0.0%  
Dividend yield (eoy) %00.4 0.0%  
Book value per share (Unadj.) Rs98.8262.3 37.7%  
Shares outstanding (eoy) m25.00155.79 16.0%   
Bonus/Rights/Conversions -ESOP-  
Price / Sales ratio x4.71.7 278.5%   
Avg P/E ratio x104.220.1 518.0%  
P/CF ratio (eoy) x66.412.2 546.1%  
Price / Book Value ratio x10.93.1 350.1%  
Dividend payout %07.4 0.0%   
Avg Mkt Cap Rs m27,008127,670 21.2%   
No. of employees `0001.42.4 55.7%   
Total wages/salary Rs m1,53515,559 9.9%   
Avg. sales/employee Rs Th4,210.930,861.4 13.6%   
Avg. wages/employee Rs Th1,132.26,387.0 17.7%   
Avg. net profit/employee Rs Th191.12,604.4 7.3%   
INCOME DATA
Net Sales Rs m5,71075,178 7.6%  
Other income Rs m123400 30.6%   
Total revenues Rs m5,83375,579 7.7%   
Gross profit Rs m46315,184 3.0%  
Depreciation Rs m1474,151 3.6%   
Interest Rs m02,843 0.0%   
Profit before tax Rs m4388,591 5.1%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m1792,247 8.0%   
Profit after tax Rs m2596,344 4.1%  
Gross profit margin %8.120.2 40.1%  
Effective tax rate %40.826.2 156.2%   
Net profit margin %4.58.4 53.8%  
BALANCE SHEET DATA
Current assets Rs m3,20931,898 10.1%   
Current liabilities Rs m2,07020,047 10.3%   
Net working cap to sales %20.015.8 126.6%  
Current ratio x1.61.6 97.5%  
Inventory Days Days7268 107.1%  
Debtors Days Days3555 63.6%  
Net fixed assets Rs m79060,715 1.3%   
Share capital Rs m50156 32.1%   
"Free" reserves Rs m2,41940,710 5.9%   
Net worth Rs m2,46940,865 6.0%   
Long term debt Rs m030,478 0.0%   
Total assets Rs m4,60596,176 4.8%  
Interest coverage xNM4.0-  
Debt to equity ratio x00.7 0.0%  
Sales to assets ratio x1.20.8 158.6%   
Return on assets %5.69.6 58.9%  
Return on equity %10.515.5 67.6%  
Return on capital %17.716.0 110.7%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m30014,402 2.1%   
Fx outflow Rs m2,01512,044 16.7%   
Net fx Rs m-1,7152,358 -72.7%   
CASH FLOW
From Operations Rs m8813,032 0.7%  
From Investments Rs m-94-6,177 1.5%  
From Financial Activity Rs mNA-9,011 0.0%  
Net Cashflow Rs m-6-2,123 0.3%  

Share Holding

Indian Promoters % 0.0 45.6 -  
Foreign collaborators % 75.0 3.5 2,142.9%  
Indian inst/Mut Fund % 0.3 8.7 3.4%  
FIIs % 15.7 21.2 74.1%  
ADR/GDR % 0.0 0.0 -  
Free float % 9.1 21.1 43.1%  
Shareholders   12,856 23,815 54.0%  
Pledged promoter(s) holding % 0.0 15.9 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare ASTRAZENECA PHARMA With:   SUVEN LIFESCIENCES  SHASUN PHARMA  PFIZER  TTK HEALTHCARE  SUN PHARMA  

Compare ASTRAZENECA PHARMA With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Trades Higher; FMCG and Banking Stocks Gain(12:30 pm)

Stock markets in India are presently trading higher. The BSE Sensex is trading up by 104 points and the NSE Nifty is trading up by 32 points.

Related Views on News

ASTRAZENECA PHARMA Announces Quarterly Results (4QFY19); Net Profit Up 204.9% (Quarterly Result Update)

May 27, 2019 | Updated on May 27, 2019

For the quarter ended March 2019, ASTRAZENECA PHARMA has posted a net profit of Rs 98 m (up 204.9% YoY). Sales on the other hand came in at Rs 2 bn (up 26.3% YoY). Read on for a complete analysis of ASTRAZENECA PHARMA's quarterly results.

JUBILANT LIFE SCIENCES Announces Quarterly Results (4QFY19); Net Profit Down 166.0% (Quarterly Result Update)

May 21, 2019 | Updated on May 21, 2019

For the quarter ended March 2019, JUBILANT LIFE SCIENCES has posted a net profit of Rs 1 bn (down 166.0% YoY). Sales on the other hand came in at Rs 24 bn (up 5.9% YoY). Read on for a complete analysis of JUBILANT LIFE SCIENCES's quarterly results.

ASTRAZENECA PHARMA 2017-18 Annual Report Analysis (Annual Result Update)

Mar 29, 2019 | Updated on Mar 29, 2019

Here's an analysis of the annual report of ASTRAZENECA PHARMA for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of ASTRAZENECA PHARMA. Also includes updates on the valuation of ASTRAZENECA PHARMA.

JUBILANT LIFE SCIENCES 2017-18 Annual Report Analysis (Annual Result Update)

Mar 28, 2019 | Updated on Mar 28, 2019

Here's an analysis of the annual report of JUBILANT LIFE SCIENCES for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of JUBILANT LIFE SCIENCES. Also includes updates on the valuation of JUBILANT LIFE SCIENCES.

ASTRAZENECA PHARMA Announces Quarterly Results (3QFY19); Net Profit Up 381.0% (Quarterly Result Update)

Feb 12, 2019 | Updated on Feb 12, 2019

For the quarter ended December 2018, ASTRAZENECA PHARMA has posted a net profit of Rs 291 m (up 381.0% YoY). Sales on the other hand came in at Rs 2 bn (up 67.4% YoY). Read on for a complete analysis of ASTRAZENECA PHARMA's quarterly results.

More Views on News

Most Popular

These 3 Smallcap Stocks are Set to Make the Most of Smallcap Rebound(Profit Hunter)

Jul 9, 2019

As the sense of normalcy returns to the markets, the rebound in the quality smallcaps could be huge.

2 Stocks from Super Investor Sanjay Bakshi's Portfolio You Can Bet On...(The 5 Minute Wrapup)

Jul 12, 2019

Despite the current fear prevailing in the markets, both these stocks have the potential to deliver in 4-5 years.

A One Stock Crorepati(Profit Hunter)

Jul 4, 2019

Do you wish you could become a crorepati in the stock market? Read on...

After Disappointing Budget, Here's a Document that Concerns Largecap and Smallcap Investors(The 5 Minute Wrapup)

Jul 8, 2019

A new 'definition' of the stock universe that triggered the smallcap sell-off is back with the latest list...

Union Budget 2019-2020: More Style Over Substance(The 5 Minute Wrapup)

Jul 5, 2019

Did the Union Budget announce measures to stimulate the economy and bolster corporate earnings growth?

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2019
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

ASTRAZENECA PHARMA SHARE PRICE


Jul 17, 2019 01:49 PM

TRACK ASTRAZENECA PHARMA

  • Track your investment in ASTRAZENECA PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON ASTRAZENECA PHARMA

ASTRAZENECA PHARMA 5-YR ANALYSIS

COMPARE ASTRAZENECA PHARMA WITH

MARKET STATS